Editorial
Gut microbia dysbiosis in non-alcoholic fatty liver disease
Translational Cancer Research
2016;
5
(Suppl 2)
:S152-S155
.
(22 August 2016)
Metformin: a promising candidate for chemoprevention of colorectal tumor and its future
Translational Cancer Research
2016;
5
(Suppl 2)
:S156-S159
.
(22 August 2016)
Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components
Translational Cancer Research
2016;
5
(Suppl 2)
:S160-S165
.
(22 August 2016)
Adjuvant therapy in early-stage small-cell lung cancer: what’s new?
Translational Cancer Research
2016;
5
(Suppl 2)
:S166-S169
.
(22 August 2016)
Recent randomized trials on stage III lung cancer treatment
Translational Cancer Research
2016;
5
(Suppl 2)
:S170-S173
.
(22 August 2016)
“Switchable chimeric antigen receptor T cells: a novel universal chimeric antigen receptor platform for a safe control of T-cell activation”
Translational Cancer Research
2016;
5
(Suppl 2)
:S174-S177
.
(22 August 2016)
Results of the REGATTA trial on surgical therapy of limited metastatic gastric cancer: open issues and future perspectives
Translational Cancer Research
2016;
5
(Suppl 2)
:S178-S181
.
(22 August 2016)
Towards prevention of metastatic prostate cancer: recent molecular insights from the direct analysis of metastatic precursor cells
Translational Cancer Research
2016;
5
(Suppl 2)
:S182-S186
.
(22 August 2016)
Genomic analysis of pancreatic cancer: a glimmer of hope for the therapy?
Translational Cancer Research
2016;
5
(Suppl 2)
:S187-S191
.
(22 August 2016)
Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction?
Translational Cancer Research
2016;
5
(Suppl 2)
:S192-S195
.
(22 August 2016)
The role of circadian clock genes in leukemia
Translational Cancer Research
2016;
5
(Suppl 2)
:S196-S198
.
(22 August 2016)
PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
Translational Cancer Research
2016;
5
(Suppl 2)
:S199-S202
.
(22 August 2016)
Positron emission tomography-CT surveillance versus neck dissection in advanced head and neck cancer: time for a paradigm shift in management
Translational Cancer Research
2016;
5
(Suppl 2)
:S203-S204
.
(22 August 2016)
Exosomes as “translational” cancer promoter organelles
Translational Cancer Research
2016;
5
(Suppl 2)
:S205-S207
.
(22 August 2016)
Trans-arterial embolization for hepatocellular carcinoma: with or without epidoxorubicin?
Translational Cancer Research
2016;
5
(Suppl 2)
:S208-S211
.
(22 August 2016)
Calculation of recurrence risk of ductal carcinoma in situ: open questions, controversies and future perspectives
Translational Cancer Research
2016;
5
(Suppl 2)
:S212-S215
.
(22 August 2016)
Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 2)
:S216-S220
.
(22 August 2016)
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
Translational Cancer Research
2016;
5
(Suppl 2)
:S221-S225
.
(22 August 2016)
Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells
Translational Cancer Research
2016;
5
(Suppl 2)
:S226-S232
.
(22 August 2016)
Tumor recurrence in patients treated with direct-acting antivirals for hepatitis C following curative therapy: a cause for concern?
Translational Cancer Research
2016;
5
(Suppl 2)
:S233-S236
.
(22 August 2016)
Promise of vandetanib, a FDA-approved RET kinase inhibitor, for the treatment of RET fusion-positive lung adenocarcinoma
Translational Cancer Research
2016;
5
(Suppl 2)
:S237-S239
.
(22 August 2016)
Pazopanib: a new therapeutic option for advanced gastrointestinal stromal tumors
Translational Cancer Research
2016;
5
(Suppl 2)
:S240-S242
.
(22 August 2016)
Actionable intelligence provided by pancreatic cancer genomic landscape: are targets for curative therapy on the map?
Translational Cancer Research
2016;
5
(Suppl 2)
:S243-S247
.
(22 August 2016)
GD3 mediated immune response via vascular endothelial growth factor in ovarian cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S248-S252
.
(22 August 2016)
HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?
Translational Cancer Research
2016;
5
(Suppl 2)
:S253-S256
.
(22 August 2016)
Functional and clinical impact of MYC mutations in diffuse large B cell lymphomas
Translational Cancer Research
2016;
5
(Suppl 2)
:S257-S260
.
(22 August 2016)
Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability
Translational Cancer Research
2016;
5
(Suppl 2)
:S261-S263
.
(22 August 2016)
TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?
Translational Cancer Research
2016;
5
(Suppl 2)
:S264-S268
.
(22 August 2016)
Crucial role of vascular endothelial growth factor in the immune system of patients with ovarian cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S269-S271
.
(22 August 2016)
Perspective
Perspective on the EF-14 trial and its implications for the role of tumor-treating fields in the management of glioblastoma
Translational Cancer Research
2016;
5
(Suppl 2)
:S272-S275
.
(22 August 2016)
Multimodality treatment in limited small cell lung cancer (L-SCLC): different perspectives about the optimal approach
Translational Cancer Research
2016;
5
(Suppl 2)
:S276-S281
.
(22 August 2016)
Emerging molecular pathways and targets in neuroendocrine prostate cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S282-S285
.
(22 August 2016)
Novel non-invasive urine-based gene expression assay discriminates between low- and high-risk prostate cancer before biopsy
Translational Cancer Research
2016;
5
(Suppl 2)
:S286-S289
.
(22 August 2016)
Benefits, limitations and opportunities of NOTCH inhibitors for treatment of glioma
Translational Cancer Research
2016;
5
(Suppl 2)
:S290-S295
.
(22 August 2016)
Commentary
Tumor-associated neutrophils: an emerging player in the immune microenvironment of hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 2)
:S296-S299
.
(22 August 2016)
The expanding role of exosomes in cancer biology and therapy
Translational Cancer Research
2016;
5
(Suppl 2)
:S300-S302
.
(22 August 2016)
Tumor-infiltrating T cells are invigorated by modulating cholesterol metabolism
Translational Cancer Research
2016;
5
(Suppl 2)
:S303-S305
.
(22 August 2016)
Epidermal growth factor receptor-tyrosine kinase inhibitors, which is the best choice?
Translational Cancer Research
2016;
5
(Suppl 2)
:S306-S308
.
(22 August 2016)
CCR5 antagonist, an ally to fight against metastatic colorectal cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S309-S312
.
(22 August 2016)
Interleukin-2 as anticancer immunotherapy in the age of checkpoint inhibition
Translational Cancer Research
2016;
5
(Suppl 2)
:S313-S314
.
(22 August 2016)
Chimeric antigen receptor T cells get passed by leukemia
Translational Cancer Research
2016;
5
(Suppl 2)
:S315-S317
.
(22 August 2016)
Pancreatic ductal adenocarcinoma—a new hope?
Translational Cancer Research
2016;
5
(Suppl 2)
:S318-S320
.
(22 August 2016)
Urinary exosome and beyond
Translational Cancer Research
2016;
5
(Suppl 2)
:S321-S324
.
(22 August 2016)
Immunoscore vs. Microsatellite instability as prognostic biomarkers in colorectal cancer: who wins?
Translational Cancer Research
2016;
5
(Suppl 2)
:S325-S327
.
(22 August 2016)
Divergent roles of miR-126 in normal and malignant stem cells
Translational Cancer Research
2016;
5
(Suppl 2)
:S328-S331
.
(22 August 2016)
Treatment improvement by addition of leucovorin to S-1 plus oxaliplatin in patients with advanced gastric cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S332-S334
.
(22 August 2016)
p-21 activated kinase 4 (PAK4) role in pancreatic cancer stem cells
Translational Cancer Research
2016;
5
(Suppl 2)
:S335-S337
.
(22 August 2016)
Helios—controller of Treg stability and function
Translational Cancer Research
2016;
5
(Suppl 2)
:S338-S341
.
(22 August 2016)
Dabrafenib in patients with BRAF-mutated non-small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S342-S344
.
(22 August 2016)
Deep sequencing reveals that low level TP53 mutations are ubiquitous in ovarian cancer patients and controls: successes and challenges for early detection
Translational Cancer Research
2016;
5
(Suppl 2)
:S345-S348
.
(22 August 2016)
Sweetening of glutamine metabolism in cancer cells by Rho GTPases through convergence of multiple oncogenic signaling pathways
Translational Cancer Research
2016;
5
(Suppl 2)
:S349-S356
.
(22 August 2016)
CRISPR/Cas9 engineering offers new opportunities to model pancreatic ductal adenocarcinoma development
Translational Cancer Research
2016;
5
(Suppl 2)
:S357-S359
.
(22 August 2016)
An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S360-S362
.
(22 August 2016)
Correspondence
Elucidating alternative pathways triggering small cell lung carcinoma tumor biology
Translational Cancer Research
2016;
5
(Suppl 2)
:S363-S365
.
(22 August 2016)
CCR5 inhibition in colorectal cancer patients
Translational Cancer Research
2016;
5
(Suppl 2)
:S366-S367
.
(22 August 2016)
Immuno-molecular characterization of colorectal cancer tumors and its clinical implications
Translational Cancer Research
2016;
5
(Suppl 2)
:S368-S370
.
(22 August 2016)
ESOGIA: a “first step” for comprehensive geriatric assessment-guided treatment in non-small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 2)
:S371-S373
.
(22 August 2016)
Long journey to prevent metachronous gastric cancer after endoscopic resection
Translational Cancer Research
2016;
5
(Suppl 2)
:S374-S376
.
(22 August 2016)
Concurrent or sequential letrozole with adjuvant breast radiotherapy: primetime for personalized radiation oncology
Translational Cancer Research
2016;
5
(Suppl 2)
:S377-S379
.
(22 August 2016)
Disclosure:
This supplement was published without any sponsorship or funding.
